Treatment of post-transplant lymphoproliferative disorder with monoclonal cd20 antibody (rituximab) after heart transplantation

Nathan D. Zilz, Lyle J. Olson, Christopher G. McGregor

Research output: Contribution to journalArticle

39 Scopus citations


Post-transplant lymphoproliferative disorder (PTLD) is a frequent and often fatal complication of organ transplantation. It most often results from an Epstein-Barr virus (EBV)-transformed B-cell clone, which expresses B-cell surface markers such as CD20. We describe a case of a heart transplant recipient who EBV seroconverted post-transplant and subsequently developed subcutaneous and lymphatic B-cell lymphoma, successfully treated with CD20 antibody (rituximab). The patient has been in remission during 10 months of clinical follow-up.

Original languageEnglish (US)
Pages (from-to)770-772
Number of pages3
JournalJournal of Heart and Lung Transplantation
Issue number7
StatePublished - Jul 24 2001


ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine
  • Transplantation

Cite this